Genprex, Inc.GNPXEarnings & Financial Report
Genprex, Inc. is a clinical-stage biotechnology company focused on developing proprietary gene therapy candidates to address unmet medical needs in oncology and rare endocrine diseases like diabetes. Operating primarily in the U.S. biopharmaceutical market, it advances its pipeline through partnerships with leading research institutions and healthcare stakeholders.
GNPX Q4 FY2022 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-6.6M
Net Profit
$-6.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-19.44
Genprex, Inc. Q4 FY2022 Financial Summary
Genprex, Inc. reported revenue of $0 for Q4 FY2022, with a net profit of $-6.5M (up 17.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-6.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2022 |
Genprex, Inc. Annual Revenue by Year
Genprex, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $0).
| Year | Annual Revenue | |
|---|---|---|
| 2022 | $0 | — |
Genprex, Inc. Quarterly Revenue & Net Profit History
Genprex, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2022 | $0 | — | $-6.5M | N/A |
| Q3 FY2022 | $0 | — | $-6.1M | N/A |
| Q2 FY2022 | $0 | — | $-5.8M | N/A |
| Q1 FY2022 | $0 | — | $-5.3M | N/A |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Assets | $39.4M | $34.6M | $29.9M | $25.1M |
| Liabilities | $2.4M | $2.2M | $2.5M | $2.8M |
| Equity | $37.0M | $32.4M | $27.5M | $22.3M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Operating CF | $-4.1M | $-4.5M | $-4.5M | $-4.5M |